Quidel Corporation Announces Joint Development and Commercialization Agreement with BioHelix Corporation
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: Less than a minute
Quidel Corporation has announced that it has entered into a joint development and commercialization agreement with BioHelix Corporation. The agreement with BioHelix focuses on the development and commercialization of in vitro molecular diagnostic tests utilizing BioHelix’s novel isothermal amplification technology.
The partnership combines BioHelix’s expertise in the research and development of nucleic acid technologies for diagnostic applications with Quidel’s strength in the development, manufacture and commercialization of diagnostic tests.
Under the partnership, Quidel will fund and jointly develop with BioHelix assays for detection of infectious pathogens in a non-instrumented, handheld format utilizing BioHelix’s isothermal amplification technology.
BioHelix undertakes primary responsibility for assay development while Quidel has primary responsibility for manufacturing, marketing and selling the new products developed under the agreement and exclusive, worldwide commercialization rights for the new products.
“We are extremely pleased with this strategic partnership as both companies look to leverage their respective strengths in bringing novel diagnostic solutions to the clinical diagnostic market,” commented Douglas Bryant, president and chief executive officer of Quidel Corporation. Huimin Kong, Ph.D., president and chief executive officer of BioHelix Corporation, added, “We are excited to work with Quidel in the further development and commercialization of simple, cost-effective molecular diagnostic tests, which is a major focus for our company.”
The partnership combines BioHelix’s expertise in the research and development of nucleic acid technologies for diagnostic applications with Quidel’s strength in the development, manufacture and commercialization of diagnostic tests.
Under the partnership, Quidel will fund and jointly develop with BioHelix assays for detection of infectious pathogens in a non-instrumented, handheld format utilizing BioHelix’s isothermal amplification technology.
BioHelix undertakes primary responsibility for assay development while Quidel has primary responsibility for manufacturing, marketing and selling the new products developed under the agreement and exclusive, worldwide commercialization rights for the new products.
“We are extremely pleased with this strategic partnership as both companies look to leverage their respective strengths in bringing novel diagnostic solutions to the clinical diagnostic market,” commented Douglas Bryant, president and chief executive officer of Quidel Corporation. Huimin Kong, Ph.D., president and chief executive officer of BioHelix Corporation, added, “We are excited to work with Quidel in the further development and commercialization of simple, cost-effective molecular diagnostic tests, which is a major focus for our company.”
